Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
60 participants
INTERVENTIONAL
2010-11-30
2011-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Moderate to Severe Facial Acne Vulgaris
NCT00612573
Treatment of Acne Vulgaris With Doryx Tablets Compared to Doxycyline Hyclate
NCT00635609
Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris
NCT02661958
A Study of the Safety, Engraftment, and Action of Multi-Dosed NB01 in Adults With Moderate Acne
NCT03709654
Efficacy and the Tolerability of the Sequential Application of Two Marketed Products in Patients With Acne Vulgaris
NCT01461655
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oral antibiotic plus soy extract
Doxycycline and S-equol
Oral doxycycline and s-equol twice a day
Oral antibiotic
Doxycycline
ORAL DOXYCYCLINE TWICE A DAY
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Doxycycline and S-equol
Oral doxycycline and s-equol twice a day
Doxycycline
ORAL DOXYCYCLINE TWICE A DAY
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Non-pregnant, non-lactating females
* Signed written informed consent form
* Must be able to understand and be willing to follow all study instructions
* Have a clinical diagnosis of acne vulgaris
Exclusion Criteria
* Any concomitant dermatologic condition that may affect outcome measures
* Concurrent use of any other medication to treat acne vulgaris
* Have a history or clinical evidence of any other active acute or chronic medical disease or condition considered by the principal investigator as unsuitable for the study
* Are currently using any other investigational agent or device
* Have participated in any other clinical study within 90 days prior to enrollment
* Employees or family members of sponsor or research site
13 Years
60 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nexgen Dermatologics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nexgen Dermatologics, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joshua M Berlin, MD
Role: PRINCIPAL_INVESTIGATOR
Study Protocol, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Palos Verdes Dermatology Associates
Rolling Hills Estates, California, United States
Berlin Center
Boynton Beach, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Howard Fein, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11022006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.